AstraZeneca has partnered with Cerulean to develop new anti-tumor drugs.

Cerulean, a troubled biopharmaceutical company in recent years, has recently finally had good news. Pharmaceutical giant AstraZeneca will join forces with the company to conduct research into anti-tumor combination therapy. The partners will study whether AstraZeneca's PARP inhibitor drug Lynparza and Cerulean's nanodrug CRLX101 can work together on tumor treatment, a study that has also attracted the attention of the U.S. National Cancer Center and will sponsor the study.
this is the first time the two companies have worked together, and for the troubled Cerulean, it's no doubt that carbon is being sent in the snow. The CRLX101 developed by Cerulean uses a nano-carrier system to deliver small doses of the highly toxic drug camptothecin directly to the tumor site to kill tumor cells. The company had high hopes for the drug. However, the complete failure of the relevant clinical phase II study in 2013 left the company in a complete slump. And so far there has been no recovery. In 2014, the company raised more than $80 million in an IPO at $7 a share.
today, the company's share price is close to $3.50, and its market capitalisation is just $85m. The bad conditions eventually sent former CEO Oliver Fetzer out of the ring, leaving one wondering how cold it was.
, however, Cerulean now seems to see hope for a reversal. The company says existing research has shown that the Lynparza-CRLX101 combination treatment program is primarily synergistic from two metabolic pathways. The strong lethal effect of CRLX101 on tumor cells can also make up for the short plate of traditional PARP inhibitor drugs that do not have enough lethal effect. Both sides will demonstrate the safety and efficacy of this combination of therapies in future clinical studies.
, Cerulean has not been idle for several years, and the company has been working on a combination of the drug and Avastin, and is expected to produce results in 2017.
.